Sarepta Therapeutics Faces Legal and Regulatory Challenges

Sarepta Therapeutics shares are trading lower after The Gross Law Firm announced a class action lawsuit alleging misleading statements about the safety risks of its gene therapy product, Elevidys. Additionally, RBC cut its price target on Sarepta from $23 to $10, citing a challenging path forward for the company.